Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The findings of a study by Alterity Therapeutics (ATH) demonstrate its ATH434 candidate is “neuroprotective” and improves motor function
  • The preclinical study was performed at the Medical University of Innsbruck in Austria under the direction of Professor Nadia Stefanova
  • Results have been published by Movement Disorders — the official journal of the International Parkinson and Movement Disorder Society
  • CEO David Stamler says ATH is on track to initiate a phase two clinical trial of the drug in patients with Multiple System Atrophy by the end of the year
  • Shares are trading 8.8 per cent higher at 3.7 cents at 2:44 pm AEST

The findings of a study by Alterity Therapeutics (ATH) have officially been published, demonstrating the company’s ATH434 drug candidate is “neuroprotective” and improves motor function.

Based in Melbourne and San Fransisco, the biotechnology company is dedicated to developing treatments for neurodegenerative conditions.

Its ATH434 candidate is reportedly the first in a new generation of small-molecule drugs designed to inhibit the accumulation and aggregation of pathological proteins implicated in neurodegeneration.

The preclinical study of the drug was performed at the Laboratory of Translational Neurodegeneration Research at the Medical University of Innsbruck in Austria, under the direction of Professor Nadia Stefanova.

The findings, published by Movement Disorders — the official journal of the International Parkinson and Movement Disorder Society — showed treatment using ATH434 was both neuroprotective and improved motor function.

Specifically, the drug was demonstrated to reduce a-synuclein-related neurodegeneration in a widely accepted murine model of Multiple System Atrophy (MSA).

ATH said the results independently confirmed and extended previous findings from another academic laboratory, both in the same MSA model and in animal models of Parkinson’s disease.

Importantly, the study also revealed for the first time that ATH343 preserved neurons in the stratium — a region of the brain known to be affected in patients with MSA.

Alterity Therapeutics CEO David Stamler said publication of the results was exactly what the company was hoping to see as it advanced to clinical trials in MSA.

“By targeting a-synuclein and excess brain iron in MSA, we believe that ATH343 can treat the underlying cause of this devastating disease, which has no approved therapy,” he said.

“We remain on track to initiate our phase two clinical trial of ATH343 in patients with MSA by the end of the calendar year.”

The full publication is available online via Movement Disorders‘ online journal.

Alterity Therapeutics shares were trading 8.8 per cent higher at 3.7 cents each at 2:44 pm AEST.

ATH by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.